Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 Feb 14;10(2):290.
doi: 10.3390/vaccines10020290.

Racial and Ethnic Diversity in SARS-CoV-2 Vaccine Clinical Trials Conducted in the United States

Lana Khalil  1 , Maranda Leary  1 , Nadine Rouphael  1   2 , Ighovwerha Ofotokun  2 , Paulina A Rebolledo  1   2 , Zanthia Wiley  1   2
Affiliations
Review

Racial and Ethnic Diversity in SARS-CoV-2 Vaccine Clinical Trials Conducted in the United States

Lana Khalil et al. Vaccines (Basel). .

Abstract

Evidence shows that White and non-Hispanic individuals are overrepresented in clinical trials. The development of new vaccines and drugs, however, necessitates that clinical research trials include representative participants, particularly in light of evidence showing that underrepresented minorities may have a different response to certain medications and vaccines. Racial and ethnic disparities among clinical trials are multilayered and complex, and this requires action. The results of this study indicate that significant racial and ethnic disparities consistently exist among the most recent early SARS-CoV-2 vaccine clinical trials as compared to the pandemic H1N1 vaccine clinical trials of 2009. New strategies, policies, training programs, and reforms are required to address these disparities among clinical trials.

Keywords: COVID-19; H1N1; clinical trials; ethnic disparities; racial disparities.

PubMed Disclaimer

Conflict of interest statement

NR receives funds from Merck, Sanofi Pasteur, Lilly, Quidel, and Pfizer. All other authors have no conflict of interest to declare.

References

    1. Centers for Disease Control and Prevention Health Equity Considerations and Racial and Ethnic Minority Groups. Centers for Disease Control and Prevention. [(accessed on 3 December 2021)]; Available online: https://www.cdc.gov/coronavirus/2019-ncov/community/health-equity/race-e....
    1. O’Callaghan K.P., Blatz A.M., Offit P.A. Developing a SARS-CoV-2 vaccine at warp speed. JAMA. 2020;324:437–438. doi: 10.1001/jama.2020.12190. - DOI - PubMed
    1. Grady C., Shah S., Miller F., Danis M., Nicolini M., Ochoa J., Taylor H., Wendler D., Rid A. So much at stake: Ethical tradeoffs in accelerating SARSCoV-2 vaccine development. Vaccine. 2020;38:6381–6387. doi: 10.1016/j.vaccine.2020.08.017. - DOI - PMC - PubMed
    1. Flores L.E., Frontera W.R., Andrasik M.P., Del Rio C., Mondríguez-González A., Price S.A., Krantz E.M., Pergam S.A., Silver J.K. Assessment of the inclusion of racial/ethnic minority, female, and older individuals in vaccine clinical trials. JAMA. 2021;4:e2037640. doi: 10.1001/jamanetworkopen.2020.37640. - DOI - PMC - PubMed
    1. Loree J.M., Anand S., Dasari A., Unger J.M., Gothwal A., Ellis L.M., Varadhachary G., Kopetz S., Overman M.J., Raghav K. Disparity of race reporting and representation in clinical trials leading to cancer drug approvals from 2008 to 2018. JAMA Oncol. 2019;5:e191870. doi: 10.1001/jamaoncol.2019.1870. - DOI - PMC - PubMed

LinkOut - more resources